ALS Limited (ASX:ALQ)

Revenue by Segment

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Commodities	1.29B	1.09B	1.09B	1.09B	886.50M
Commodities Growth	18.84%	0.22%	-0.05%	22.63%	41.89%
Life Sciences	2.03B	1.91B	1.38B	-	-
Life Sciences Growth	6.05%	38.94%	-	-	-
Life Sciences Excl Nuvisan	-	-	-	1.19B	1.07B
Life Sciences Excl Nuvisan Growth	-	-	-	11.90%	-
Elimination Nuvisan	-	-	-	-142.00M	-73.80M
Life Sciences - Nuvisan	-	-	-	142.00M	73.80M
Life Sciences - Nuvisan Growth	-	-	-	92.41%	-
Total	3.32B	3.00B	2.46B	2.28B	1.95B
Total Growth	10.69%	21.85%	8.00%	16.77%	10.81%

Revenue by Geography

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Africa	74.80M	65.50M	57.60M	54.50M	45.50M
Africa Growth	14.20%	13.72%	5.69%	19.78%	31.12%
Asia/Pacific	949.90M	854.10M	810.10M	764.60M	647.20M
Asia/Pacific Growth	11.22%	5.43%	5.95%	18.14%	-3.75%
EMENA (Europe, Middle East, North Africa)	1.17B	1.05B	594.10M	514.50M	478.90M
EMENA (Europe, Middle East, North Africa) Growth	11.75%	75.98%	15.47%	7.43%	2.79%
Americas	1.13B	1.03B	999.80M	945.70M	780.30M
Americas Growth	8.97%	3.45%	5.72%	21.20%	32.61%
Total	3.32B	3.00B	2.46B	2.28B	1.95B
Total Growth	10.69%	21.85%	8.00%	16.77%	10.82%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 19, 2026

Data Sources Report a data error